The primary objective of our systematic review and meta-analysis was to examine the efficacy of SGLT2 inhibitors compared to placebo for reduction of all-cause and cardiovascular mortality, heart failure events (HFEs), readmissions, and symptomatic improvement in patients admitted for acute heart failure. The gene discussed is SLC5A2; the disease is heart failure.